Hanna Koivunoro1, Leena Kankaanranta2, Tiina Seppälä2, Aaro Haapaniemi3, Antti Mäkitie3, Heikki Joensuu4. 1. Department of Oncology, Helsinki University Hospital and University of Helsinki, Finland; Neutron Therapeutics Finland Ltd, Helsinki, Finland. 2. Department of Oncology, Helsinki University Hospital and University of Helsinki, Finland. 3. Department of Otorhinolaryngology - Head and Neck Surgery, Helsinki University Hospital and University of Helsinki, Finland. 4. Department of Oncology, Helsinki University Hospital and University of Helsinki, Finland. Electronic address: heikki.joensuu@hus.fi.
Abstract
BACKGROUND AND PURPOSE: Head and neck squamous cell carcinoma (HNSCC) that recurs locally is a therapeutic challenge. We investigated the efficacy of boron neutron capture therapy (BNCT) in the treatment of such patients and the factors associated with treatment response and survival. METHODS AND MATERIALS: Seventy-nine patients with inoperable, locally recurred HNSCC were treated with l-boronophenylalanine-mediated BNCT in Espoo, Finland, between February, 2003 and January, 2012. Prior treatments consisted of surgery and conventionally fractionated radiotherapy to a median cumulative dose of 66 Gy (interquartile range [IQR], 59-70 Gy) administered with or without concomitant chemotherapy. Tumor response was assessed using the RECISTv.1.0 criteria. RESULTS: Forty patients received BNCT once (on 1 day), and 39 twice. The median time between the 2 treatments was 6 weeks. Forty-seven (68%; 95% confidence interval [CI], 57-79%) of the 69 evaluable patients responded; 25 (36%) had a complete response, 22 (32%) a partial response, 17 (25%) a stable disease lasting for a median of 4.2 months, and 5 (7%) progressed. The patients treated with BNCT twice responded more often than those treated once. The median follow-up time after BNCT was 7.8 years. The 2-year locoregional progression-free survival rate was 38% and the overall survival rate 21%. A high minimum tumor dose and a small volume were independently associated with long survival in a multivariable analysis. CONCLUSIONS: Most patients responded to BNCT. A high minimum tumor dose from BNCT was predictive for response and survival.
BACKGROUND AND PURPOSE: Head and neck squamous cell carcinoma (HNSCC) that recurs locally is a therapeutic challenge. We investigated the efficacy of boron neutron capture therapy (BNCT) in the treatment of such patients and the factors associated with treatment response and survival. METHODS AND MATERIALS: Seventy-nine patients with inoperable, locally recurred HNSCC were treated with l-boronophenylalanine-mediated BNCT in Espoo, Finland, between February, 2003 and January, 2012. Prior treatments consisted of surgery and conventionally fractionated radiotherapy to a median cumulative dose of 66 Gy (interquartile range [IQR], 59-70 Gy) administered with or without concomitant chemotherapy. Tumor response was assessed using the RECISTv.1.0 criteria. RESULTS: Forty patients received BNCT once (on 1 day), and 39 twice. The median time between the 2 treatments was 6 weeks. Forty-seven (68%; 95% confidence interval [CI], 57-79%) of the 69 evaluable patients responded; 25 (36%) had a complete response, 22 (32%) a partial response, 17 (25%) a stable disease lasting for a median of 4.2 months, and 5 (7%) progressed. The patients treated with BNCT twice responded more often than those treated once. The median follow-up time after BNCT was 7.8 years. The 2-year locoregional progression-free survival rate was 38% and the overall survival rate 21%. A high minimum tumor dose and a small volume were independently associated with long survival in a multivariable analysis. CONCLUSIONS: Most patients responded to BNCT. A high minimum tumor dose from BNCT was predictive for response and survival.
Authors: V V Kanygin; A I Kasatova; E L Zavjalov; I A Razumov; S I Kolesnikov; A I Kichigin; O I Solov'eva; A R Tsygankova; S Yu Taskaev; D A Kasatov; T V Sycheva; V A Byvaltsev Journal: Bull Exp Biol Med Date: 2022-01-10 Impact factor: 0.804
Authors: Eleanor A Blakely; Bruce Faddegon; Christopher Tinkle; Charles Bloch; Michael Dominello; Robert J Griffin; Michael C Joiner; Jay Burmeister Journal: J Appl Clin Med Phys Date: 2019-10-01 Impact factor: 2.243
Authors: Wolfgang A G Sauerwein; Lucie Sancey; Evamarie Hey-Hawkins; Martin Kellert; Luigi Panza; Daniela Imperio; Marcin Balcerzyk; Giovanna Rizzo; Elisa Scalco; Ken Herrmann; PierLuigi Mauri; Antonella De Palma; Andrea Wittig Journal: Life (Basel) Date: 2021-04-10
Authors: Timothy D Malouff; Danushka S Seneviratne; Daniel K Ebner; William C Stross; Mark R Waddle; Daniel M Trifiletti; Sunil Krishnan Journal: Front Oncol Date: 2021-02-26 Impact factor: 6.244